Diastika Biotekindo Tbk PT

Diastika Biotekindo Tbk PT maintains a strong liquidity position, with a current ratio of 4.41, indicating that it holds significantly more current assets than current liabilities. The company's liquidity is further supported by a substantial cash and equivalents balance of IDR 50,019,482,560, which is well above the typical liquidity needs for a firm in the medical equipment and distribution industry. However, the company reported negative operating cash flow of IDR -43,150,544,260 and free cash flow of IDR -4,187,527,380, suggesting that it is currently investing heavily in operations or experiencing cash outflows from core activities. In terms of profitability, Diastika Biotekindo Tbk PT generates a return on equity (ROE) of 6.64% and a return on assets (ROA) of 5.4%, which are metrics that align with the industry's preferred performance indicators. These returns are in line with the typical performance of firms in the medical equipment and distribution sector, where capital efficiency and asset utilization are key drivers of profitability. The company's operating income of IDR 23,153,085,590 and net income of IDR 14,023,055,380 reflect a healthy gross margin of approximately 38.3%, which is consistent with the industry's average profitability. The company's revenue is primarily concentrated in Indonesia, with no disclosed international operations. This geographic concentration may expose the company to local economic and regulatory risks, although it also allows for a focused operational strategy. The company's total revenue of IDR 201,306,181,380 is derived from its core medical equipment and services business, with no material diversification into other segments. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The company's capital expenditure of IDR -28,438,205,630 indicates ongoing investment in infrastructure and operations, which may support future growth but also contributes to the current negative free cash flow. The company's debt-to-equity ratio of 0.09 suggests a conservative capital structure, with minimal reliance on debt financing, which reduces financial risk. The risk assessment for Diastika Biotekindo Tbk PT indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong equity position reduce the likelihood of near-term financial distress. Additionally, the absence of dilution risk suggests that the company is not currently issuing new shares at a pace that would significantly dilute existing shareholders. The company's conservative capital structure and strong liquidity position further support this low-risk profile. Recent filings and transcripts do not indicate any material events or strategic shifts that would significantly impact the company's operations or financial performance. The company's financial statements and disclosures remain consistent with its historical performance, and there are no signs of emerging risks or opportunities that would alter the current outlook.